New Horizons in the Treatment of Osteosarcoma
- 25 November 2021
- journal article
- review article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 385 (22), 2066-2076
- https://doi.org/10.1056/nejmra2103423
Abstract
Osteosarcoma, which is most common in people 10 to 30 years of age, is generally treated with resection and adjuvant chemotherapy. Detection of gene rearrangements, copy-number variations, and targeted disruption of tumor suppressors by whole-genome sequencing has not yet led to improved treatment.Keywords
This publication has 66 references indexed in Scilit:
- DNA deaminases induce break-associated mutation showers with implication of APOBEC3B and 3A in breast cancer kataegiseLife, 2013
- Mutational Processes Molding the Genomes of 21 Breast CancersCell, 2012
- A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid TumorsClinical Cancer Research, 2012
- Incidence of neoplasia in Diamond Blackfan anemia: a report from the Diamond Blackfan Anemia RegistryBlood, 2012
- Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer DevelopmentCell, 2011
- Cancer-germline gene expression in pediatric solid tumors using quantitative real-time PCRInternational Journal of Cancer, 2006
- Presurgical Chemotherapy Compared With Immediate Surgery and Adjuvant Chemotherapy for Nonmetastatic Osteosarcoma: Pediatric Oncology Group Study POG-8651Journal of Clinical Oncology, 2003
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- The Effect of Adjuvant Chemotherapy on Relapse-Free Survival in Patients with Osteosarcoma of the ExtremityThe New England Journal of Medicine, 1986
- CONTRIBUTION TO THE KNOWLEDGE OF SARCOMAAnnals of Surgery, 1891